Perfuse Therapeutics announced that the US Food and Drug Administration has cleared the Investigational New Drug application for a Phase 1/2a clinical study of PER-001 Intravitreal Implant in patients with glaucoma.
Perfuse Therapeutics announced that the US Food and Drug Administration has cleared the Investigational New Drug application for a Phase 1/2a clinical study of PER-001 Intravitreal Implant in patients with glaucoma.